On 17 December 2010, orphan designation (EU/3/10/823) was granted by the European Commission to Dimensione Ricerca S.r.l., Italy, for lomitapide for the treatment of familial chylomicronaemia.
The sponsorship was transferred to Aegerion Pharmaceuticals, France, in February 2012 and subsequently to Aegerion Pharmaceuticals Limited, United Kingdom, in February 2015.
The sponsorship was transferred to Amryt Pharmaceuticals Designated Activity Company, Ireland, in March 2019.
|Disease / condition||
Treatment of familial chylomicronaemia
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;